Vaccine Formulation and Adjuvants are crucial components in the development of effective vaccines, enhancing their immunogenicity and efficacy. Vaccine formulation refers to the precise composition and preparation of vaccines, including the selection of antigens, adjuvants, stabilizers, and delivery systems. The primary goal of vaccine formulation is to stimulate a robust and long-lasting immune response against specific pathogens while ensuring safety and stability. This involves identifying and selecting antigens that are capable of eliciting an immune response and formulating them in a manner that enhances their stability and immunogenicity.
Adjuvants are substances added to vaccines to enhance the immune response to antigens. They work by activating and modulating the innate immune system, increasing antigen presentation and promoting the production of antibodies and memory cells. Common adjuvants include aluminum salts, oil-in-water emulsions, and saponins. The selection of adjuvants depends on various factors, including the type of antigen, the desired immune response, and safety considerations. Adjuvants can improve vaccine efficacy by reducing the amount of antigen required per dose, allowing for dose sparing and increasing the duration and magnitude of the immune response.
In addition to adjuvants, vaccine formulation may also include stabilizers, preservatives, and excipients to enhance vaccine stability, shelf-life, and safety. Stabilizers help protect vaccines from degradation during storage and transport, while preservatives prevent microbial growth and contamination. Excipients such as buffers and pH adjusters maintain the pH and osmolarity of the vaccine formulation, ensuring compatibility with the body's tissues.
Title : A universal AI design framework and brokerage platform for democratised manufacturing of mRNA therapeutics
Duccio Medini, BioForge, United States
Title : Personalized and Precision Medicine (PPM) via biodesign-driven translational applications and upgraded business modeling to secure the human biosafety: The next-step vaccinomics of the future
Sergey V Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Development of VSV-vector based vaccine against H5N1 avian influenza by targeting both H5N1 hemagglutinin and matrix protein 2
Zhujun Ao, University of Manitoba, Canada
Title : A novel responsive microneedle platform for reliable drug and vaccine delivery
Huanhuan Li, Queen’s University Belfast, United Kingdom
Title : Emerging nanovaccine strategies for enhanced immune targeting and vaccine performance
Aysel Sadayli, V.Y. Axundov Scientific-Research Institute of Medical Prophylaxis, Azerbaijan
Title : The promise of nanotechnology in Personalized & Precision Medicine: Nano-driven precision vaccinomics of the future
Sergey V Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Reaching zero-dose children through adaptive immunization strategies in security-compromised areas of Zamfara State, Nigeria
Attahir Abubakar, Ahmadu Bello University, Nigeria
Title : Comparative efficacy of different H9N2 avian influenza virus inactivated vaccines using some commercially available adjuvants for superior control in broilers
Ayman H M El Deeb, Cairo University, Egypt
Title : Structure-based design and development of next-generation Respiratory Syncytial Virus (RSV) vaccine
Lei Chen, Yikang Biotech Suzhou Co., Ltd, China
Title : Unmasking urban immunization inequities: A cross-sectional LQAS analysis of zero-dose drivers in slum and non-slum settings of Uttar Pradesh, India
Ashish Kumar Maurya, John Snow India, India